Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.
Guimarães PO, Lopes RD, Wojdyla DM, Abdul-Rahim AH, Connolly SJ, Flaker GC, Wang J, Hanna M, Granger CB, Wallentin L, Lees KR, Alexander JH, McMurray JJV. Guimarães PO, et al. Among authors: flaker gc. Cardiovasc Drugs Ther. 2017 Jun;31(3):295-301. doi: 10.1007/s10557-017-6728-z. Cardiovasc Drugs Ther. 2017. PMID: 28516318 Free article.
Practical management of atrial fibrillation.
Alexander C, Flaker GC. Alexander C, et al. Among authors: flaker gc. South Med J. 1999 Dec;92(12):1136-43. South Med J. 1999. PMID: 10624902 Review.
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators. Flaker GC, et al. Am Heart J. 2006 Nov;152(5):967-73. doi: 10.1016/j.ahj.2006.06.024. Am Heart J. 2006. PMID: 17070169
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ. Healey JS, et al. Stroke. 2008 May;39(5):1482-6. doi: 10.1161/STROKEAHA.107.500199. Epub 2008 Mar 6. Stroke. 2008. PMID: 18323500 Clinical Trial.
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D, Connolly SJ. Eikelboom JW, et al. Am Heart J. 2010 Mar;159(3):348-353.e1. doi: 10.1016/j.ahj.2009.08.026. Am Heart J. 2010. PMID: 20211294 Clinical Trial.
Cognitive function and anticoagulation control in patients with atrial fibrillation.
Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, Anand IS, Hart R, Connolly SJ; Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) Investigators. Flaker GC, et al. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):277-83. doi: 10.1161/CIRCOUTCOMES.109.884171. Epub 2010 Mar 16. Circ Cardiovasc Qual Outcomes. 2010. PMID: 20233976 Clinical Trial.
172 results